Bicara Therapeutics Inc. released a corporate presentation highlighting its lead program, ficerafusp alfa (FICERA), a bifunctional EGFR-directed antibody combined with a TGF-β ligand trap. The company outlined clinical data for FICERA plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including confirmed objective response rates around 48% to 54% across evaluated cohorts, deep tumor shrinkage in a majority of responders, and median overall survival of 21.3 months in an efficacy-evaluable HPV-negative population. Bicara also presented safety summaries for weekly and every-two-week dosing regimens and described ongoing development plans, including a pivotal study with an interim analysis targeted for mid-2027 and exploration in additional solid tumors such as metastatic colorectal cancer. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.